1. Home
  2. DVAX vs MD Comparison

DVAX vs MD Comparison

Compare DVAX & MD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • MD
  • Stock Information
  • Founded
  • DVAX 1996
  • MD 1979
  • Country
  • DVAX United States
  • MD United States
  • Employees
  • DVAX N/A
  • MD N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • MD Hospital/Nursing Management
  • Sector
  • DVAX Health Care
  • MD Health Care
  • Exchange
  • DVAX Nasdaq
  • MD Nasdaq
  • Market Cap
  • DVAX 1.3B
  • MD 1.2B
  • IPO Year
  • DVAX 2004
  • MD 1995
  • Fundamental
  • Price
  • DVAX $9.70
  • MD $16.13
  • Analyst Decision
  • DVAX Buy
  • MD Buy
  • Analyst Count
  • DVAX 4
  • MD 7
  • Target Price
  • DVAX $26.50
  • MD $16.79
  • AVG Volume (30 Days)
  • DVAX 1.9M
  • MD 769.9K
  • Earning Date
  • DVAX 11-06-2025
  • MD 10-31-2025
  • Dividend Yield
  • DVAX N/A
  • MD N/A
  • EPS Growth
  • DVAX N/A
  • MD N/A
  • EPS
  • DVAX N/A
  • MD 1.29
  • Revenue
  • DVAX $316,268,000.00
  • MD $1,940,725,000.00
  • Revenue This Year
  • DVAX $23.23
  • MD N/A
  • Revenue Next Year
  • DVAX $16.57
  • MD $3.09
  • P/E Ratio
  • DVAX N/A
  • MD $12.45
  • Revenue Growth
  • DVAX 26.66
  • MD N/A
  • 52 Week Low
  • DVAX $9.20
  • MD $10.39
  • 52 Week High
  • DVAX $14.63
  • MD $17.67
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 41.54
  • MD 49.85
  • Support Level
  • DVAX $9.20
  • MD $16.51
  • Resistance Level
  • DVAX $9.94
  • MD $17.06
  • Average True Range (ATR)
  • DVAX 0.30
  • MD 0.40
  • MACD
  • DVAX -0.05
  • MD -0.20
  • Stochastic Oscillator
  • DVAX 40.65
  • MD 4.64

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About MD Pediatrix Medical Group Inc.

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

Share on Social Networks: